{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Ftoga-podcast.simplecast.com%2Fepisodes%2Falk-treatment-considerations-in-nsclc-Or12u7M2","width":444,"version":"1.0","type":"rich","title":"ALK treatment considerations in NSCLC","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/5a6dee0e-98c8-446a-adf3-3c6d8e5e6b37/d9f3738f-48ff-414c-b5ab-e072dacffbb7/toga-podcast-16-lung-cancer-alk-3kx3k.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/7c344940-b9b7-46b8-8e10-8db666338f17\" height=\"200\" width=\"100%\" title=\"ALK treatment considerations in NSCLC\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this episode, Mal Itchins, Medical Oncologist discusses ALK therapy choices & considerations when treating ALK NSCLC. Mal is joined by Steven Kao, Medical Oncologist from the Chris O’Brien Lifehouse and Lisa Briggs who has her own personal experience with ALK lung cancer having been diagnosed in 2014, when only limited treatment options were available."}